European Committee on Antimicrobial Susceptibility Testing

Recommendations

Info

Pasteurella multocida EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Penicillins MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Benzylpenicillin 0.5 0.5 1 unit 17 17 Disk diffusion (EUCAST standardised disk diffusion method) Medium: Mueller-Hinton agar + 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F) Inoculum: McFarland 0.5 Incubation: 5% CO 2 , 35±1ºC, 18±2h Reading: Read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. Quality control: Haemophilus influenzae ATCC 49766. For control of the inhibitor component of beta-lactam inhibitor-combination disks, use Staphylococcus aureus ATCC 29213. Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Ampicillin 1 1 Note A Note A 1. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. Amoxicillin 1 1 Note A Note A A. Infer susceptibility from benzylpenicillin susceptibility. Amoxicillin-clavulanic acid 1 1 1 1 2-1 15 15 Cephalosporins MIC breakpoint Disk Zone diameter Notes (mg/L) content breakpoint Numbered notes relate to general comments and/or MIC breakpoints. (µg) (mm) Lettered notes relate to the disk diffusion method. S ≤ R > S ≥ R < Cefotaxime 0.03 0.03 5 26 26 Fluoroquinolones MIC breakpoint Disk Zone diameter Notes (mg/L) content breakpoint Numbered notes relate to general comments and/or MIC breakpoints. (µg) (mm) Lettered notes relate to the disk diffusion method. S ≤ R > S ≥ R < Ciprofloxacin 0.06 0.06 5 27 A 27 A Levofloxacin 0.06 0.06 5 27 A 27 A A. The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. B. Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. 75
Pasteurella multocida EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Tetracyclines MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Doxycycline 1 1 Note A Note A Tetracycline (screen) NA NA 30 24 A 24 A Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. A. Susceptibility inferred from tetracycline screen test. Miscellaneous agents MIC breakpoint (mg/L) Disk content Zone diameter breakpoint Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. (µg) (mm) S ≤ R > S ≥ R < Trimethoprim-sulfamethoxazole 1 0.25 0.25 1.25-23.75 23 23 1. Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. 76
Page 1 and 2:
European C
Page 3 and 4:
Guidance on reading EUCAST Breakpoi
Page 5 and 6:
Version 7.0, 2017-01-01 Acinetobact
Page 7 and 8:
Enterobacteriaceae EUCAST Clinical
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Pseudomonas spp. EUCAST Clinical Br
Page 15 and 16:
Pseudomonas spp. EUCAST Clinical Br
Page 17 and 18:
Acinetobacter spp. EUCAST Clinical
Page 19 and 20:
Acinetobacter spp. EUCAST Clinical
Page 21 and 22:
Staphylococcus spp. EUCAST Clinical
Page 23 and 24:
Staphylococcus spp. EUCAST Clinical
Page 25 and 26: Staphylococcus spp. EUCAST Clinical
Page 27 and 28: Enterococcus spp. EUCAST Clinical B
Page 29 and 30: Enterococcus spp. EUCAST Clinical B
Page 31 and 32: Streptococcus groups A, B, C and G
Page 37 and 38: Streptococcus pneumoniae EUCAST Cli
Page 43 and 44: Viridans group streptococci EUCAST
Page 45 and 46: Viridans group streptococci EUCAST
Page 47 and 48: Haemophilus influenzae EUCAST Clini
Page 53 and 54: Moraxella catarrhalis EUCAST Clinic
Page 55 and 56: Moraxella catarrhalis EUCAST Clinic
Page 57 and 58: Neisseria gonorrhoeae EUCAST Clinic
Page 59 and 60: Neisseria gonorrhoeae EUCAST Clinic
Page 61 and 62: Neisseria meningitidis EUCAST Clini
Page 63 and 64: Neisseria meningitidis EUCAST Clini
Page 65 and 66: Gram-positive anaerobes except Clos
Page 67 and 68: Gram-positive anaerobes except Clos
Page 69 and 70: Clostridium difficile EUCAST Clinic
Page 71 and 72: Gram-negative anaerobes EUCAST Clin
Page 73 and 74: Gram-negative anaerobes EUCAST Clin
Page 75: Listeria monocytogenes EUCAST Clini
Page 79 and 80: Corynebacterium spp. EUCAST Clinica
Page 81 and 82: Aerococcus sanguinicola and urinae
Page 83 and 84: Kingella kingae EUCAST Clinical Bre
Page 85 and 86: Mycobacterium tuberculosis EUCAST C
Page 87 and 88: PK/PD (Non-species related) breakpo
Page 89 and 90: PK/PD (Non-species related) breakpo
Page 91 and 92: Dosages EUCAST Clinical Breakpoint
Page 93 and 94: Dosages EUCAST Clinical Breakpoint
show all

European Committee on Antimicrobial Susceptibility Testing

Create successful ePaper yourself

Delete template?

Save as template?